← Leaderboards
Charles L Sentman
Dartmouth College
$10,805,711
Attributed
$10,805,711
Total exposure
11
Grants
10
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.3M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$10,805,711 · 11
By mechanism
R01$4,693,703 · 3
T32$3,297,878 · 1
R21$1,798,500 · 4
R61$704,198 · 1
P30$311,432 · 1
P01$0 · 1
Top collaborators
No co-investigators on record.
Most similar at Dartmouth College
Same institution · by research overlap
- Marc S Ernstoff$5,989,395
- Steven D Leach$25,866,740
- Scott A. Gerber$7,545,727
- Eric R Henderson$2,461,790
- Steven Fiering$14,075,746
Others in their field
Top investigators on “Immune”
- Lawrence Corey · Fred Hutchinson Cancer Center$680,290,567
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$541,067,641
- Bambra Strokes · Ppd Development Lp$526,656,217
- Barton F Haynes · Duke University$470,748,611
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$342,310,423
- Judith S. Currier · University Of California Los Angeles$334,425,492
Research focus
ImmuneMalignant NeoplasmsImmune SystemCell TherapyImmunotherapyCancer ImmunotherapyProteinsNeoplastic CellDesignImmunityImmunobiologyAlzheimer&AposInnovationLeukocytesNovel StrategiesVaccinationMacrophageAffectMelanomaTumor MicroenvironmentAreaCancer PatientRegulatory T-LymphocyteCells
Grant awards (41)
Enhanced persistence of CAR Tregs in the CNS for Alzheimerâs disease therapy$704,198
R61 · FY2025 · AG · contact PI
Immunomodulatory and behavioral effects of CAR T regulatory cell therapy for Alzheimer's Diseaseâ.$205,000
R21 · FY2024 · AG · contact PI
Immunomodulatory and behavioral effects of CAR T regulatory cell therapy for Alzheimer's Diseaseâ.$246,000
R21 · FY2023 · AG · contact PI
Cell therapy using neurodegenerative disease modifying molecules (NDMMs) as a means to modulate oxidative damage and neuronal survival in ALS$451,000
R21 · FY2020 · NS · contact PI
Chimeric antigen receptor T regulatory cells as therapy for Alzheimer's Disease$451,000
R21 · FY2020 · AG · contact PI
Immunobiology of Myeloid and Lymphoid Cells$443,943
T32 · FY2020 · AI · contact PI
Immunobiology of Myeloid and Lymphoid Cells$426,178
T32 · FY2019 · AI · contact PI
Developing human regulatory T cells that are engineered to target mutant SOD1$243,000
R21 · FY2019 · NS · contact PI
Immunobiology of Myeloid and Lymphoid Cells$424,971
T32 · FY2018 · AI · contact PI
Developing human regulatory T cells that are engineered to target mutant SOD1$202,500
R21 · FY2018 · NS · contact PI
Immunology & Cancer Immunotherapy (ICI)$72,409
P30 · FY2018 · CA · contact PI
Immunology & Cancer Immunotherapy (ICI)$6,056
P30 · FY2018 · CA · contact PI
Immunology & Cancer Immunotherapy (ICI)$5,342
P30 · FY2018 · CA · contact PI
Immunology & Cancer Immunotherapy (ICI)$4,790
P30 · FY2018 · CA · contact PI
Immunology & Cancer Immunotherapy (ICI)$3,213
P30 · FY2018 · CA · contact PI
Immunology & Cancer Immunotherapy (ICI)$1,665
P30 · FY2018 · CA · contact PI
A novel NKG2D-specific BiTE cancer immunotherapy$336,150
R01 · FY2017 · CA · contact PI
Immunology & Cancer Immunotherapy (ICI)$74,371
P30 · FY2017 · CA · contact PI
Immunology & Cancer Immunotherapy (ICI)$1,120
P30 · FY2017 · CA · contact PI
Immunobiology of Myeloid and Lymphoid Cells$404,593
T32 · FY2016 · AI · contact PI
A novel NKG2D-specific BiTE cancer immunotherapy$336,150
R01 · FY2016 · CA · contact PI
Immunology & Cancer Immunotherapy (ICI)$72,423
P30 · FY2016 · CA · contact PI
Immunobiology of Myeloid and Lymphoid Cells$405,666
T32 · FY2015 · AI · contact PI
A novel NKG2D-specific BiTE cancer immunotherapy$336,150
R01 · FY2015 · CA · contact PI
Immunology & Cancer Immunotherapy (ICI)$70,043
P30 · FY2015 · CA · contact PI
Immunobiology of Myeloid and Lymphoid Cells$397,741
T32 · FY2014 · AI · contact PI
A novel NKG2D-specific BiTE cancer immunotherapy$326,066
R01 · FY2014 · CA · contact PI
Immunobiology of Myeloid and Lymphoid Cells$395,233
T32 · FY2013 · AI · contact PI
A novel NKG2D-specific BiTE cancer immunotherapy$335,113
R01 · FY2013 · CA · contact PI
Immunobiology of Myeloid and Lymphoid Cells$399,553
T32 · FY2012 · AI · contact PI
Chimeric NKG2D receptors in ovarian cancer immunotherapy$321,839
R01 · FY2012 · CA · contact PI
Chimeric NKG2D receptors in ovarian cancer immunotherapy$321,839
R01 · FY2011 · CA · contact PI
Chimeric NKG2D receptors in ovarian cancer immunotherapy$331,793
R01 · FY2010 · CA · contact PI
Chimeric NKG2D receptors in ovarian cancer immunotherapy$331,793
R01 · FY2009 · CA · contact PI
Chimeric NKG2D receptors in ovarian cancer immunotherapy$331,793
R01 · FY2008 · CA · contact PI
NK effector mechanisms during NK-lymphoma interactions$266,666
R01 · FY2007 · CA · contact PI
NK effector mechanisms during NK-lymphoma interactions$274,631
R01 · FY2006 · CA · contact PI
NK effector mechanisms during NK-lymphoma interactions$281,240
R01 · FY2005 · CA
NK effector mechanisms during NK-lymphoma interactions$281,240
R01 · FY2004 · CA
NK effector mechanisms during NK-lymphoma interactions$281,240
R01 · FY2003 · CA
Sex hormone regulation of NK cell in reproductive system$0
P01 · FY2002 · AI